Psoriasis Trial, Recruiting NCT06258668 Sponsor: Bristol-Myers Squibb Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT06258668
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 19 years of age or older
  • You have been diagnosed with moderate-to-severe plaque psoriasis
  • Your doctor has determined that you are a suitable candidate for light therapy or systemic (whole-body) medication
  • You are about to start taking deucravacitinib as directed by the approved guidelines for this medication

Who may not be able to join:

  • You are being prescribed deucravacitinib for a reason that has not been officially approved in Korea
  • You have a health condition or other factor that means deucravacitinib is not considered safe for you to take, according to the official Korean prescribing guidelines set by the Ministry of Food and Drug Safety

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 August 2024
Est. completion
30 September 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Number of participants with adverse events (AEs); Number of participants with adverse drug reactions (ADRs); Number of participants with serious adverse events (SAEs); Number of participants with serious adverse drug reactions (SADRs); Number of participants with unexpected adverse events (AEs); Number of participants with unexpected adverse drug reactions (ADRs); Number of participants with unexpected serious adverse events (SAEs); Number of participants with unexpected serious adverse drug reactions (SADRs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov